Needham Maintains Buy on AtriCure, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on AtriCure (NASDAQ:ATRC) and raises the price target from $44 to $46.
February 16, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a Buy rating on AtriCure and raises the price target from $44 to $46.
The upgrade in the price target by a reputable analyst like Mike Matson from Needham suggests a positive outlook on AtriCure's stock. This is likely to instill confidence in investors and could lead to a short-term increase in the stock price. The direct mention and specific action (raising the price target) highlight the significance of this news for ATRC.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100